Not independent
Tenure on this board
9.7 yrs
Meeting calendar
BNTC · Annual meeting · Monday, December 1, 2025
Benitec Biopharma Inc
2 nominees · 3 ballot items.
The 2025 Benitec Biopharma annual meeting includes three proposals: election of two Class III directors (Dr. Jerel Banks and Megan Boston), ratification of Baker Tilly US, LLP as independent auditor for FY2026, and a non-binding Say-on-Pay vote on executive compensation.
Market cap
$436M
1Y TSR
-22.3%
Board grade
C
Record date
Oct 10, 2025
Filing
DEF 14A
Meeting concluded · Dec 1, 2025
Follow how the vote landed and what changed on Benitec Biopharma Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors (Class III
ManagementBoard: FORElection of two Class III directors to hold office until our 2028 annual meeting; nominees are Dr. Jerel Banks and Megan Boston.
- 2
Ratification of the Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatification of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026.
- 3
Advisory Vote on Executive Compensation
ManagementBoard: FORA non-binding advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement.
Director elections
Nominees on the ballot2
Not independent
Tenure on this board
9.8 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 33.6% | 11,548,351 | $123M |
| 2 | JANUS HENDERSON GROUP PLC | 8.4% | 2,876,380 | $31M |
| 3 | FRANKLIN RESOURCES INC | 6.9% | 2,366,308 | $25M |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.2% | 2,120,672 | $23M |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 5.4% | 1,850,000 | $20M |
| 6 | Nantahala Capital Management, LLC | 4.2% | 1,438,371 | $15M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2.7% | 931,556 | $10M |
| 8 | INFINITUM ASSET MANAGEMENT, LLC | 2.7% | 923,006 | $10M |
| 9 | Alyeska Investment Group, L.P. | 2.2% | 750,000 | $8M |
| 10 | SILVERARC CAPITAL MANAGEMENT, LLC | 2.1% | 717,725 | $8M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Benitec Biopharma Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Seer IncSEER
Annual meeting·Jul 28, 2026·$91M
Reference
Frequently asked questions
- When is the Benitec Biopharma Inc 2025 annual meeting?
- Benitec Biopharma Inc (BNTC) holds its 2025 annual shareholder meeting on Monday, December 1, 2025.
- What is the record date for the Benitec Biopharma Inc 2025 meeting?
- The record date for the Benitec Biopharma Inc 2025 meeting is Friday, October 10, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Benitec Biopharma Inc's 2025 meeting?
- The board is presenting 2 director nominees at the Benitec Biopharma Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Benitec Biopharma Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Benitec Biopharma Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.